Inogen, Inc. (NASDAQ:INGN) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. reduced its position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 51.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,282 shares of the medical technology company's stock after selling 77,489 shares during the period. D. E. Shaw & Co. Inc. owned about 0.31% of Inogen worth $672,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of INGN. Tudor Investment Corp ET AL boosted its position in Inogen by 44.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 82,852 shares of the medical technology company's stock valued at $760,000 after purchasing an additional 25,681 shares during the period. Dimensional Fund Advisors LP lifted its stake in Inogen by 25.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock valued at $5,574,000 after buying an additional 123,208 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Inogen by 23.5% during the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock valued at $1,160,000 after acquiring an additional 24,082 shares during the period. Prudential Financial Inc. grew its position in shares of Inogen by 141.5% during the fourth quarter. Prudential Financial Inc. now owns 360,002 shares of the medical technology company's stock worth $3,301,000 after acquiring an additional 210,961 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Inogen by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company's stock worth $128,000 after acquiring an additional 3,031 shares during the last quarter. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Price Performance

Shares of NASDAQ:INGN remained flat at $6.53 on Thursday. The stock had a trading volume of 138,036 shares, compared to its average volume of 240,048. The firm has a market capitalization of $175.57 million, a P/E ratio of -2.90 and a beta of 1.63. Inogen, Inc. has a 12 month low of $5.70 and a 12 month high of $13.33. The company's 50 day moving average price is $6.80 and its 200-day moving average price is $8.60.

Inogen (NASDAQ:INGN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.27. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. The firm had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. On average, equities research analysts expect that Inogen, Inc. will post -1.73 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on INGN shares. Stifel Nicolaus reduced their target price on shares of Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Wall Street Zen cut Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th. Finally, Needham & Company LLC upgraded Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price objective for the company in a research report on Thursday, May 22nd.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.